S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:PYPD

PolyPid (PYPD) Stock Price, News & Analysis

$5.00
+0.30 (+6.38%)
(As of 03/28/2024 ET)
Today's Range
$5.00
$5.50
50-Day Range
$4.64
$6.99
52-Week Range
$3.57
$14.70
Volume
4,573 shs
Average Volume
7,489 shs
Market Capitalization
$24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PYPD stock logo

About PolyPid Stock (NASDAQ:PYPD)

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PYPD Stock Price History

PYPD Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
PolyPid Ltd. (PYPD)
PolyPid's Earnings: A Preview
See More Headlines
Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PYPD
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-23,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.27) per share

Miscellaneous

Free Float
3,612,000
Market Cap
$24 million
Optionable
Optionable
Beta
1.43
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Ms. Dikla Czaczkes Akselbrad (Age 51)
    CEO & Director
    Comp: $422.33k
  • Ms. Dalit Hazan (Age 53)
    Executive Vice President of R&D and Clinical & Regulatory Affairs
    Comp: $312.25k
  • Mr. Ori Warshavsky (Age 46)
    Chief Operating Officer - US
    Comp: $335.52k
  • Mr. Jonny Missulawin (Age 37)
    Chief Financial Officer
  • Ms. Maria Rubin
    Vice President of Operations
  • Mr. Tal Vilnai
    General Counsel & Corporate Secretary
  • Ms. Rivi Lev-ari
    Vice President of Human Resource
  • Dr. Jean-Marc Hagai Pharm.D.
    Chief Commercial Officer

PYPD Stock Analysis - Frequently Asked Questions

Should I buy or sell PolyPid stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PYPD shares.
View PYPD analyst ratings
or view top-rated stocks.

How have PYPD shares performed in 2024?

PolyPid's stock was trading at $3.80 at the beginning of the year. Since then, PYPD shares have increased by 31.6% and is now trading at $5.00.
View the best growth stocks for 2024 here
.

When is PolyPid's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PYPD earnings forecast
.

How were PolyPid's earnings last quarter?

PolyPid Ltd. (NASDAQ:PYPD) issued its quarterly earnings data on Wednesday, February, 14th. The company reported ($3.97) EPS for the quarter, missing analysts' consensus estimates of ($2.17) by $1.80.

When did PolyPid's stock split?

PolyPid shares reverse split on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of PolyPid own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO).

When did PolyPid IPO?

PolyPid (PYPD) raised $50 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets served as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

Who are PolyPid's major shareholders?

PolyPid's stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of PolyPid?

Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PYPD) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners